Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes

Summary

Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.